Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for GLILD in CVID
2024-517667-23-00Phase 2Authorised
- Sponsor
- Oslo University Hospital
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in Granulomatous-lymphocytic interstitial lung disease (GLILD) and common variable immunodeficiency (CVID) comparing Rituximab with Placebo (2 arms). Primary endpoint: DLCO at Week 27. Planned start Jun 2025; status: authorised.
02
Drugs
rituximab
03
Conditions
Granulomatous-lymphocytic interstitial lung disease (GLILD)common variable immunodeficiency (CVID)
Beyond the preview
Go deeper on 2024-517667-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517667-23-00.